To better understand the role of FFA modulation on vascular function in those with metabolic syndrome, we conducted a combined, post hoc analysis of two randomised‐controlled trials assessing the effects of acipimox and salsalate on FFA reduction and insulin‐mediated, endothelium‐dependent vasodilation. This evidence concerns the gene INS and metabolic syndrome.